Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 306-320

  Katzka, D A ^a,b   Loftus Jr , E V ^a,b   Camilleri, M ^a,b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AIN 457; ANGIOPEPTIN; APILIMOD; BRIAKINUMAB; BRODALUMAB; CEFITUXIMAB; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; CLOPIDOGREL; GLUCOCORTICOID; GLUTAMINE; GOLIMUMAB; GROWTH HORMONE; IMATINIB; INFLIXIMAB; MONOCLONAL ANTIBODY; OCTREOTIDE; OMEPRAZOLE; PF 04236921; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; SECUKINUMAB; TEDUGLUTIDE; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR KINOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ARTICLE; CELIAC DISEASE; CLINICAL RESEARCH; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG SELECTIVITY; DRUG SPECIFICITY; EOSINOPHILIC ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IRRITABLE COLON; LOADING DRUG DOSE; MENETRIER DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; SHORT BOWEL SYNDROME; STOMACH PARESIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

CELIAC DISEASE; EOSINOPHILIC ESOPHAGITIS; ESOPHAGITIS, PEPTIC; GASTRITIS, HYPERTROPHIC; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-12; INTERLEUKIN-23; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865424516     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.77     Document Type: Article

References (82)

1. Ronkainen, J. et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut 56, 615-620 (2007). (Pubitemid 46662925)
2. Kerlin, P., Jones, D., Remedios, M. & Campbell, C. Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus. J. Clin. Gastroenterol. 41, 356-361 (2007). (Pubitemid 46573061)
3. Abonia, J.P. & Rothenberg, M.E. Eosinophilic esophagitis: rapidly advancing insights. Annu. Rev. Med. 63, 421-434 (2012).
4. Stein, M.L. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118, 1312-1319 (2006). (Pubitemid 44872890)
5. Straumann, A. et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59, 21-30 (2010).
6. Blanchard, C. et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J. Allergy Clin. Immunol. 120, 1292-1300 (2007). (Pubitemid 350225686)
7. Konikof, M.R. et al. A randomized, double-blind, placebo-controlled trial of futicasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 131, 1381-1391 (2006).
8. Caldwell, J.M. et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J. Allergy Clin. Immunol. 125, 879-888.e8 (2010).
9. Lucendo, A.J., De Rezende, L., Comas, C., Caballero, T. & Bellón, T. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. Am. J. Gastroenterol. 103, 2184-2193 (2008).
10. Blanchard, C. et al. Eotaxin-3 and a uniquely conserved gene-expression profle in eosinophilic esophagitis. J. Clin. Invest. 116, 536-547 (2006). (Pubitemid 43228372)
11. Okuyama, M. et al. Roles of ZO-1 and epidermal growth factor in esophageal epithelial defense against acid. Digestion 75, 135-141 (2007). (Pubitemid 47343967)
12. Souza, R.F. et al. Gastroesophageal refux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137, 1776-1784 (2009).
13. Rieder, F., Biancani, P., Harnett, K., Yerian, L. & Falk, G.W. Infammatory mediators in gastroesophageal refux disease: impact on esophageal motility, fbrosis, and carcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G571-G581 (2010).
14. Rosemary, J. & Adithan, C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical signifcance. Curr. Clin. Pharmacol. 2, 93-109 (2007). (Pubitemid 46729082)
15. Wang, Y. et al. Infuence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur. J. Clin. Pharmacol. 66, 563-569 (2010).
16. Egan, L.J., Myhre, G.M., Mays, D.C., Dierkhising, R.A., Kammer, P. & Murray, J.A. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal refux disease: variant alleles predict gastric acid suppression, but no esophageal acid exposure or refux symptoms. Aliment. Pharmacol. Ther. 17, 1521-1528 (2003). (Pubitemid 36831443)
17. Li, X.Q., Andersson, T.B., Ahlström, M. & Weidolf, L. Comparison of inhibitory efects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 32, 821-827 (2004). (Pubitemid 38955611)
18. Reynoso, D. & Trent, J.C. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr. Opin. Oncol. 22, 330-335 (2010).
19. Marrari, A., Trent, J.C. & George, S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr. Opin. Oncol. 22, 336-341 (2010).
20. Cofrey, R.J., Washington, M.K., Corless, C.L. & Heinrich, M.C. Menetrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J. Clin. Invest. 117, 70-80 (2007). (Pubitemid 46048451)
21. Settle, S.H. et al. Chronic treatment of Ménétrier's disease with Erbitux: clinical efcacy and insight into pathophysiology. Clin. Gastroenterol. Hepatol. 3, 654-659 (2005). (Pubitemid 40984725)
22. Fiske, W.H. et al. Efcacy of cetuximab in the treatment of Menetrier's disease. Sci. Transl. Med. 1, 8ra18 (2009).
23. Moore, J.K., West, S.R. & Robins, G. Advances in celiac disease. Curr. Opin. Gastroenterol. 27, 112-118 (2011).
24. Tye-Din, J.A. et al. The efects of AVL300 predigestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 134, 289-295 (2010).
25. Kapoerchan, V.V. et al. Design, synthesis and evaluation of high-afnity binders for the celiac disease associated HLA-DQ2 molecule. Mol. Immunol. 47, 1091-1097 (2010).
26. Liang, L., Pinier, M., Leroux, J.C. & Subirade, M. Interaction of a-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease. Biopolymers 95, 418-428 (2009).
27. Jeppesen, P.B. et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54, 1224-1231 (2005). (Pubitemid 41192479)
28. Jeppesen, P.B., Gilroy, R., Pertkiewicz, M., Allard, J.P., Messing, B. & O'Keefe, S.J. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fuid requirements in patients with short bowel syndrome. Gut 60, 902-914 (2011).
29. Compher, C. et al. Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. JPEN. J. Parenter. Enteral Nutr. 35, 603-609 (2011).
30. Mouksassi, M.S., Marier, J.F., Cyran, J. & Vinks, A.A. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin. Pharmacol. Ther. 86, 667-671 (2009).
31. Strober, W. & Fuss, I.J. Proinfammatory cytokines in the pathogenesis of infammatory bowel diseases. Gastroenterology 140, 1756-1767 (2011).
32. Villablanca, E.J., Cassani, B., von Andrian, U.H. & Mora, J.R. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for infammatory bowel diseases. Gastroenterology 140, 1776-1784 (2011).
33. Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60, 780-787 (2011).
34. Sandborn, W.J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257-65.e1 (2012).
35. Vandepapeliere, P. et al. Safety, immunogenicity and clinical phase I-II results of TNFα-kinoid immunotherapeutic in Crohn's disease patients. Gastroenterology 140 (suppl. 1), S123 (2011).
36. Burakof, R. et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Infamm. Bowel Dis. 12, 558-565 (2006).
37. Sands, B.E. et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Infamm. Bowel Dis. 16, 1209-1218 (2010).
38. Mannon, P.J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004). (Pubitemid 39482500)
39. Panaccione, R. et al. Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease. Am. J. Gastroenterol. 105 (suppl. 1), S457-S458 (2010).
40. Sandborn, W.J. et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141 (2008).
41. Sandborn, W.J. et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the Certif trial. Gastroenterology 140 (suppl. 1), S109 (2011).
42. Hueber, W. et al. Inhibition of IL-17A by secukinumab is inefective for Crohn's disease. J. Crohn's Colitis 5, S7 (2011).
43. Amgen. Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40. Press release, 24 October 2011 http://wwwext.amgen.com/media/media-pr-detail.jsp?year =2011&releaseID=1620695.
44. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996; discussion 947 (2004). (Pubitemid 38451170)
45. Sandborn, W.J., Ghosh, S., Panes, J., Vranic, I., Spanton, J. & Niezychowski, W. Phase 2 randomized study of CP-690,550, an oral Janus kinase inhibitor, in active Crohn's disease. Gastroenterology 140 (suppl. 1), S124 (2011).
46. Sandborn, W.J. et al. Phase 2 study of CP690,550, an oral Janus kinase inhibitor, in active ulcerative colitis. Gastroenterology 140 (suppl. 1), S110 (2011).
47. Yacyshyn, B.R. et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142 (1998). (Pubitemid 28243898)
48. Schreiber, S. et al. Absence of efcacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120, 1339-1346 (2001). (Pubitemid 32322307)
49. Yacyshyn, B.R. et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51, 30-36 (2002). (Pubitemid 34717740)
50. Warnke, C. et al. Natalizumab and progressive multifocal leukoencephalopathy\what are the causal factors and can it be avoided? Arch. Neurol. 67, 923-930 (2010).
51. Feagan, B.G. et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7-integrin. N. Engl. J. Med. 352, 2499-2507 (2005). (Pubitemid 41007865)
52. Feagan, B.G. et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7-integrin. Clin. Gastroenterol. Hepatol. 6, 1370-1377 (2008).
53. Takeda. Takeda announces primary endpoints met for pivotal phase 3 trial of VEDOLIZUMAB in patients with moderately to severely active ulcerative colitis in patients who have failed at least one conventional therapy\GEMINI I trial met endpoints of improvement in clinical response in induction and clinical remission in maintenance. Press release, 21 February 2012 http://www. takeda.com/press/article-45046.html.
54. Rutgeerts, P. et al. A phase I study of rHuMab beta 7 in moderate to severe ulcerative colitis. Gastroenterology 140 (suppl. 1), S125 (2011).
55. Vermeire, S. et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60, 1068-1075 (2011).
56. Walter, M.J. et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of infammatory bowel disease. J. Pharmacol. Exp. Ther. 335, 61-69 (2010).
57. Keshav, S., Johnson, D., Bekker, P. & Schall, T.J. PROTECT-1 study demonstrated efcacy of the intestine-specifc chemokine receptor antagonist CCX282-B(Trafcet-EN) in treatment of patients with moderate to severe Crohn's disease. Gastroenterology 136 (suppl. 1), A65 (2009).
58. Keshav, S., Johnson, D., Schall, T. & Bekker, P. Chemokine receptor-9 antagonist CCX282-B (Trafcet-EN) maintained remission of Crohn's disease in PROTECT-1 study. Gastroenterology 138 (suppl. 1), S86 (2010).
59. Mayer, L. et al. A randomized, placebo-controlled trial of MDX-100, an anti-IP-10 antibody, for moderately to severely active ulcerative colitis. Gastroenterology 139, e17-e18 (2010).
60. Ejskjaer, N. et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 29, 1179-1187 (2009).
61. Ejskjaer, N. et al. Safety and efcacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol. Motil. 22, 1069-e281 (2010).
62. Wo, J.M. et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting-randomised clinical study subset data. Aliment. Pharmacol. Ther. 33, 679-688 (2011).
63. Ang, D. et al. Infuence of ghrelin on the gastric accommodation refex and on meal-induced satiety in man. Neurogastroenterol. Motil. 21, 528-33, e8 (2009).
64. McCallum, R. et al. TZP-102, ghrelin agonist phase 2 data: the improvement in symptoms of gastroparesis (nausea, early satiety, bloating and abdominal pain) signifcantly correlated with patient rating of overall treatment efect. Gastroenterology 140, S807 (2011).
65. Shin, A. et al. Randomized, placebo-controlled, single-dose, crossover study of the efects of RM-131 in type 2 diabetics with documented delayed gastric emptying [abstr.]. Gastroenterology 142, S839 (2012).
66. Dukes, G.E. et al. Safety/tolerability, pharmacokinetics (PK), and efect on gastric emptying (GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterology and Motility Meeting, Boston, MA, 26-29 August (2010).
67. Kim, D.Y. & Camilleri, M. Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 95, 2698-2709 (2000).
68. De Maeyer, J.H., Lefebvre, R.A. & Schuurkes, J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20, 99-112 (2008).
69. Camilleri, M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin. Pharmacol. Ther. 91, 44-59 (2012).
70. Camilleri, M., Kerstens, R., Rykx, A. & Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358, 2344-2354 (2008). (Pubitemid 351749158)
71. Barrett, K.E. & Keely, S.J. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu. Rev. Physiol. 62, 535-572 (2000). (Pubitemid 30618274)
72. Joo, N.S., London, R.M., Kim, H.D., Forte, L.R. & Clarke, L.L. Regulation of intestinal Cl-and HCO3-secretion by uroguanylin. Am. J. Physiol. 274, G633-G644 (1998).
73. Donowitz, M. et al. NHERF family and NHE3 regulation. J. Physiol. (Lond.) 567, 3-11 (2005). (Pubitemid 41167297)
74. Lembo, A.J. et al. Efcacy of linaclotide for patients with chronic constipation. Gastroenterology 138, 886-95.e1 (2010).
75. Wong, B.S., Camilleri, M., McKinzie, S., Burton, D., Grafner, H. & Zinsmeister, A.R. Efects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am. J. Gastroenterol. 106, 2154-2164 (2011).
76. Chey, W.D., Camilleri, M., Chang, L., Rikner, L. & Grafner, H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am. J. Gastroenterol. 106, 1803-1812 (2011).
77. Jcong, I.D. et al. A randomised, placebo-controlled trial comparing the efects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment. Pharamcol. Ther. (2012); e-pub ahead of print 21 February 2012.
78. Tuteja, A.K., Fang, J.C., Al-Suqi, M., Stoddard, G.J. & Hale, D.C. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome-a pilot study. Scand. J. Gastroenterol. (2012); e-pub ahead of print 12 July 2012.
79. Hellström, P.M., Hein, J., Bytzer, P., Björnssön, E., Kristensen, J. & Schambye, H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment. Pharmacol. Ther. 29, 198-206 (2009).
80. Camilleri, M. Efect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G120-G128 (2012).
81. Houghton, L.A., Fell, C., Whorwell, P.J., Jones, I., Sudworth, D.P. & Gale, J.D. Efect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56, 1218-1225 (2007). (Pubitemid 47300421)
82. Iturrino, J., Camilleri, M., Busciglio, I., Burton, D. & Zinsmeister, A.R. Efect of the a2d ligand, pregabalin, on colonic sensory and motor functions in healthy adults. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G377-G384 (2011).